Company / Working Capital
VYNE Therapeutics Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$49.6M
FY2025
5-year range
$49.6M / $88.4M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $88M to $50M over the past 2 years.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of -5.5%.
Declined from $88M to $50M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -5.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.5%, indicating a declining trend.
- In FY2025, working capital increased 0.0% year-over-year.
- Peak working capital was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.6M | +0.0% |
| FY2024 | $49.6M | -43.9% |
| FY2023 | $88.4M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $65.8M | -2.7% |
| FY2019 | $67.7M | -47.9% |
| FY2018 | $130.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026